A Type II CDK6 Degrader Enables Cellular Targeting beyond the Limits of Type II Inhibition

Ji Hyeon Kim

Department of Chemical and Systems Biology, ChEM-H, and Stanford Cancer Institute, Stanford School of Medicine

Caitlin E. Mills

Laboratory of Systems Pharmacology, Department of Systems Biology

Zuzanna Kozicka

Department of Medical Oncology

Daniel C. Scott

Department of Structural Biology

Cyrus Jin

Department of Cancer Biology

Zixuan Jiang

Department of Chemical and Systems Biology, ChEM-H, and Stanford Cancer Institute, Stanford School of Medicine

Brendan G. Dwyer

Department of Chemical and Systems Biology, ChEM-H, and Stanford Cancer Institute, Stanford School of Medicine

Qixiang Geng

Department of Chemical and Systems Biology, ChEM-H, and Stanford Cancer Institute, Stanford School of Medicine

Sean T. Toenjes

Department of Chemical and Systems Biology, ChEM-H, and Stanford Cancer Institute, Stanford School of Medicine

Woong Sub Byun

Department of Chemical and Systems Biology, ChEM-H, and Stanford Cancer Institute, Stanford School of Medicine

Dina ElHarouni

Department of Pathology

Hongyu Li

Keith L. Ligon

Abby M. Thornhill

Department of Cancer Biology

Hannah M. Jones

Department of Chemical and Systems Biology, ChEM-H, and Stanford Cancer Institute, Stanford School of Medicine

Bryan A. Romero

Department of Chemical and Systems Biology, ChEM-H, and Stanford Cancer Institute, Stanford School of Medicine

Stephen M. Hinshaw

Department of Chemical and Systems Biology, ChEM-H, and Stanford Cancer Institute, Stanford School of Medicine

Benjamin L. Ebert

Department of Medical Oncology

Brenda A. Schulman

Katherine A. Donovan

Eric S. Fischer

Nathanael S. Gray